Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF V600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysisChristian U. Blank, Michael P. Brown, Paola Queirolo et al.|European Journal of Cancer|2017Cited by 36
Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN studyFrancesc Bosch, Véronique Leblond, Guy Cantin et al.|Leukemia|2019Cited by 12